We are live on ! Find out more
CCP

Clough Capital Partners Portfolio holdings

AUM $1.23B
1-Year Est. Return 51.32%
This Fund
S&P 500
This Quarter Est. Return
+12.83%
1 Year Est. Return
+51.32%
3 Year Est. Return
+175.14%
5 Year Est. Return
+243.7%
10 Year Est. Return
+1,533.05%
AUM
$1.92B
AUM Growth
+$48.8M
Cap. Flow
-$111M
Cap. Flow %
-5.8%
Top 10 Hldgs %
24.29%
Holding
225
New
42
Increased
41
Reduced
78
Closed
51

Sector Composition

Rank Sector Weight
1 Energy 20.21%
2 Communication Services 18.98%
3 Financials 12.2%
4 Consumer Discretionary 12.02%
5 Healthcare 11.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GWPH
101
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.74M 0.25%
35,700
+32,000
+865% +$3.06M
SUNS
102
DELISTED
SLR Senior Investment Corp. Common Stock
SUNS
$4.73M 0.25%
+292,000
New +$4.84M
BAX icon
103
Baxter International
BAX
$12.3B
$4.71M 0.25%
99,000
+87,000
+725% +$4.1M
CVLT icon
104
Commault Systems
CVLT
$5.94B
$4.5M 0.23%
84,700
-27,200
-24% -$1.37M
WNS
105
DELISTED
WNS Holdings
WNS
$4.4M 0.23%
+146,900
New +$4.23M
CHCT
106
Community Healthcare Trust
CHCT
$420M
$4.38M 0.23%
200,000
HTGC icon
107
Hercules Capital
HTGC
$3.3B
$4.38M 0.23%
322,900
+69,200
+27% +$923K
OTIC
108
DELISTED
Otonomy, Inc.
OTIC
$4.33M 0.23%
238,103
-104,200
-30% -$1.7M
LGF
109
DELISTED
Lions Gate Entertainment
LGF
$4.3M 0.22%
215,100
+6,500
+3% +$133K
KURA icon
110
Kura Oncology
KURA
$1.01B
$4.19M 0.22%
670,859
-77,180
-10% -$391K
CLLS
111
Cellectis
CLLS
$162M
$3.69M 0.19%
153,350
-18,200
-11% -$476K
KDNY
112
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$3.63M 0.19%
+58,440
New +$4.13M
AZN icon
113
AstraZeneca
AZN
$251B
$3.41M 0.18%
51,836
+271
+0.5% +$17.7K
LKFT
114
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$3.12M 0.16%
48,170
-16,800
-26% -$947K
PBH icon
115
Prestige Consumer Healthcare
PBH
$2.21B
$3.01M 0.16%
62,300
-8,400
-12% -$425K
ADX icon
116
Adams Diversified Equity Fund
ADX
$3.18B
$2.89M 0.15%
219,530
MANU icon
117
Manchester United
MANU
$3.44B
$2.82M 0.15%
166,832
-7,700
-4% -$127K
ITCI
118
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.62M 0.14%
171,850
-53,800
-24% -$2.18M
USA icon
119
Liberty All-Star Equity Fund
USA
$1.8B
$2.6M 0.14%
501,693
-44,800
-8% -$231K
TXMD icon
120
TherapeuticsMD
TXMD
$25M
$2.55M 0.13%
7,490
-600
-7% -$219K
DOC
121
DELISTED
PHYSICIANS REALTY TRUST
DOC
$2.38M 0.12%
110,700
+88,800
+405% +$1.88M
UAM
122
DELISTED
Universal American Corp
UAM
$2.26M 0.12%
295,373
-14,500
-5% -$107K
NMFC icon
123
New Mountain Finance
NMFC
$682M
$1.9M 0.1%
+138,113
New +$1.89M
BGS icon
124
B&G Foods
BGS
$257M
$1.71M 0.09%
+34,700
New +$1.67M
PGEN icon
125
Precigen
PGEN
$2.51B
$1.52M 0.08%
54,921
-3,078
-5% -$81.4K

Similar funds

Clough Capital Partners's Q3 2016 Portfolio in Review

As of Q3 2016, Clough Capital Partners held 225 positions worth $1.92B, up 2.6% from $1.87B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Clough Capital Partners withdrew a net $111M in Q3 2016, closing 51 positions and reducing 78 holdings. Its most notable exit was Lam Research, an estimated $54M position sold in full.

By sector, the portfolio is most concentrated in Energy at 20% of assets, down from 25% a quarter earlier, followed by Communication Services and Financials.

Against the trend, Clough Capital Partners opened a new position in EOG Resources worth $26.8M.

  • Clough Capital Partners's largest Q3 2016 buy was EOG Resources: 277,600 shares worth $26.8M.
  • Clough Capital Partners added most to Alphabet (Google) Class C in Q3 2016, an estimated $30.8M increase.
  • Clough Capital Partners's biggest Q3 2016 reduction was Tivity Health, Inc. Common Stock, cutting an estimated $19.1M.
  • Clough Capital Partners fully exited Lam Research in Q3 2016, selling an estimated $54M.
  • Clough Capital Partners's ten largest holdings make up 24% of its $1.92B portfolio in Q3 2016.
  • Clough Capital Partners opened 42 new positions and closed 51 in Q3 2016.
  • Clough Capital Partners's portfolio value rose 2.6% quarter-over-quarter to $1.92B.

Based on Clough Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.